Ahmad Tarhini, MD, PhD, professor and senior member in cutaneous oncology and immunology at Moffitt Cancer Center, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma. With a longstanding focus on improving immunotherapy outcomes and mitigating treatment-related toxicities, Tarhini and his team aim to bridge critical knowledge gaps in precision oncology through this work.
Of Interest
Gene-based blood test may predict melanoma recurrence
Researchers evaluated a blood test’s ability to predict recurrence in patients with stage 3 melanoma.
Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma
Stergios J. Moschos, MD, an associate professor of medicine in the Department of Medicine in the Division of Oncology at the University of North Carolina (UNC) Chapel Hill School of Medicine, UNC Health, emphasized the importance of appropriately administering bridging therapy to patients who are slated to receive the adoptive T-cell therapy lifileucel (Amtagvi).
Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition
Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.